• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

GlaxoSmithKline (GSK) - Articles and news items

asthma-severe

NICE recommends first-in-class severe asthma treatment

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

Mepolizumab is the first biologic treatment to target specific white blood cells called eosinophils, which are responsible for symptoms of severe asthma…

injectable-hiv

ViiV Healthcare to evaluate injectable HIV treatment

Industry news / 23 November 2016 / Niamh Louise Marriott, Digital Content Producer

The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve…

globe-pill

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

Emma Walmsley

First female CEO to lead GSK as Emma Walmsley succeeds Andrew Witty

Industry news / 20 September 2016 / Niamh Louise Marriott, Digital Content Producer

She will succeed Andrew Witty as GSK CEO, when he retires on 31st March 2017. She will be the first female CEO of a major global pharmaceuticals company…

rheumatoid-arthritis

Janssen submits EU application for rheumatoid arthritis drug

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis…

global hiv treatment

Global dual-drug trial aims to advance HIV treatment

Industry news / 16 August 2016 / ViiV Healthcare

ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had no prior antiretroviral therapy…

GSK UoL collaborate cancer treatment

GSK teams up with University of Leicester in search of cancer treatments

Industry news / 21 July 2016 / Niamh Louise Marriott, Digital Content Producer

global pharmaceutical company GlaxoSmithKline has been established to discover and develop novel medicines to treat aggressive forms of blood cancer…

MenABCWY

MenABCWY set to revolutionise the meningococcal vaccine market

Industry news / 29 June 2016 / Victoria White, Digital Content Producer

GlobalData says MenABCWY has the potential to significantly change the approach used to prevent meningococcal disease…

Benlysta

Greater response with GSK’s Benlysta vs placebo in SLE study

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

Patients with SLE experienced a significantly greater response to treatment with Benlysta administered via subcutaneous injection compared to placebo…

Sirukumab

Sirukumab meets both co-primary endpoints in rheumatoid arthritis study

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis…

hiv

From HIV to oncology: widening access through flexible IP

Blog, Z Homepage promo / 28 April 2016 / Jon Pender, VP Government Affairs, GSK

Jon Pender, GSK, discusses how a flexible and thoughtful approach to IP can help get medicines to the poorest and hardest-to-reach patients around the world…

gsk

GSK adopts groundbreaking IP approach to expand access to its medicines

Industry news / 31 March 2016 / Victoria White

Sir Andrew Witty has set out a series of steps designed to help bring innovative GSK medicines to more people living in the world’s poorest countries…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +